A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Stopped early · Phase 1

Conditions studied: Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer

In brief

This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.

Key facts

Study ID: NCT04982926
Run by: Taiho Oncology, Inc.
People needed: 29
Starts: 2021-09-16
Expected to finish: 2025-03-24
Last updated by the study team: 2025-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted
Have adequate organ function
ECOG PS 0-1
Dose Escalation:
Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO
Any solid tumor with EGFR and / or HER2 aberration
Dose Expansion:
Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma)
Cohort A: Non-small cell lung cancer (NSCLC)
Cohort B: HER2 positive breast cancer
Cohort C: Recurrent or refractory glioblastoma
Cohort D: Other solid tumors with EGFR or HER2 aberrations

You may not qualify if…

Non-stable brain metastases
Have significant cardiovascular disorder
Have not recovered from prior cancer treatment
A serious illness or medical condition

Where it is running

Tennessee Oncology — Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center — Houston, Texas, United States
CLCC Gustave Roussy — Villejuif, Cedex, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.